- 1 Association between angiotensin-converting enzyme inhibitors and angiotensin II
- 2 receptor blockers use and the risk of infection and clinical outcome of COVID-19: a
- 3 comprehensive systematic review and meta-analysis.
- 4 Guangbo Qu, MD^{1a}, Liqin Shu, MD^{2a}, Evelyn J. Song, MD³, Dhiran Verghese, MD⁴, John
- 5 Patrick Uy, MD⁴, Ce Cheng, DO⁵, Qin Zhou, PhD⁶, Hongru Yang MD⁷, Zhichun Guo MD⁷,
- 6 Mengshi Chen, MD⁸, Chenyu Sun, MD, MSc^{4,*}
- 7 1. Department of Epidemiology and Health Statistics, School of Public Health, Anhui
- 8 Medical University, No. 81 Meishan Road, Hefei 230032, Anhui, China.
- 9 2. Department of Child Health care, Maternal and Child Health Care Hospital of Anhui
- 10 Province (Affiliated Maternal and Child Health Care Hospital of Anhui Medical University),
- Hefei 230001, Anhui, China.
- 3. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD,
- 13 USA.
- 4. AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 60657,
- 15 Illinois, USA
- 5. Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville 28304,
- 17 NC, USA
- 18 6. Mayo Clinic, Rochester, MN 55905, USA
- 19 7. Massachusetts College of Pharmacy and Health Science, 179 Longwood Ave, Boston,
- 20 02115, MA, USA
- 8. Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public
- 22 Health, Central South University.
- a. Guangbo Qu and Liqin Shu contributed equally to this study and should be considered as
- 24 co-joint first authors.
- 25 *Correspondence to: Chenyu Sun, Internal Medicine, AMITA Health Saint Joseph Hospital
- 26 Chicago, Lake Shore Drive Chicago, Illinois 60657, Chicago, USA. E-mail:
- 27 drsunchenyu@yeah.net.
- Short title: ACEIs and ARBs use and COVID-19 risk

Abstract

1

Background The effect of using Angiotensin-converting enzyme inhibitors (ACEIs) and
 Angiotensin-receptor blockers (ARBs) on the risk of coronavirus disease 2019 (COVID-19)

4 is a topic of recent debate. Although studies have examined the potential association between

5 them, the results remain controversial. This study aims to determine the true effect of

6 ACEI/ARBs use on the risk of infection and clinical outcome of COVID-19.

7 Methods Five electronic databases (PubMed, Web of science, Cochrane library, China

8 National Knowledge Infrastructure database, medRxiv preprint server) were retrieved to find

9 eligible studies. Meta-analysis was performed to examine the association between

ACEI/ARBs use and the risk of infection and clinical outcome of COVID-19.

11 Results 22 articles containing 157,328 patients were included. Use of ACEI/ARBs was not

associated with increased risk of infection (Adjusted OR: 0.96, 95% CI: 0.91-1.01, $I^2=5.8\%$)

or increased severity (Adjusted OR: 0.90, 95% CI: 0.77-1.05, I^2 =27.6%) of COVID-19. The

use of ACEI/ARBs was associated with lower risk of death from COVID-19 (Adjusted OR:

15 0.66, 95% CI: 0.44-0.99, I^2 =57.9%). Similar results of reduced risk of death were also found

for ACEI/ARB use in COVID-19 patients with hypertension (Adjusted OR: 0.36, 95% CI:

17 0.17-0.77, $I^2=0$).

18 Conclusion This study provides evidence that ACEI/ARBs use for COVID-19 patients does

19 not lead to harmful outcomes and may even provide a beneficial role and decrease mortality

20 from COVID-19. Clinicians should not discontinue ACEI/ARBs for patients diagnosed with

21 COVID-19 if they are already on these agents.

Keywords: COVID-19; Angiotensin-converting enzyme inhibitor; Angiotensin-receptor 1

2 blockers; risk; systematic review; meta-analysis.

1. Introduction

3

4

21

5 In December 2019, the first case of novel coronavirus disease (COVID-19) caused by 6 7 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, 8 China [1, 2]. Due to the rapidly increasing number of cases worldwide, on March 11, 2020, 9 the World Health Organization (WHO) declared the COVID-19 outbreak a global pandemic As of June 3, 2020, there were 6, 287, 771 confirmed cases and 379, 941 deaths globally per 10 11 WHO [3]. COVID-19 has greatly impacted both professional and personal lives of everyone 12 worldwide. The epidemiological and clinical characteristics of COVID-19 have been well described 13 in previous studies [4, 5]. Hypertension, diabetes and cardiovascular diseases (CVD) 14 15 including congestive heart failure (CHF) and myocardial infarction are common 16 comorbidities reported in patients with COVID-19 and have been associated with a poor 17 prognosis [5, 6]. Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin-receptor blockers (ARBs) are first line anti-hypertensive medications and are 18 included in the guideline-directed therapy for diabetic nephropathy, CHF and myocardial 19 20 infarction. Angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase, is

widely expressed in certain tissues of human body including lung, intestine, heart, and

4 kidneys, and it has been shown that the use of ACEIs and ARBs can increase the expression 1 2 of ACE2 [7, 8]. Furthermore, ACE2 acts as a functional receptor and SARS-CoV-2 utilizes the ACE2 for attachment of its spike protein, in the process of its entrance into cells [9,10]. 3 4 These findings led some investigators to hypothesize that the use of ACEIs or ARBs may 5 increase the risk of infection by SARS-CoV-2 and the severity of COVID-19 [11-13]. Several clinical studies have been conducted to test this hypothesis. However, a 6 7 consensus has not been reached regarding how the use of ACEIs or ARBs affects the outcome 8 of patients with COVID-19. The goal of this meta-analysis is to clarify the effects of ACEIs 9 and/or ARBs on the infection risk, severity, and mortality of COVID-19, hoping to shed more 10 light in the prevention and treatment of the current ongoing pandemic. 11 2. Methods 12 13 This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14]. 14 15 2.1 Literature search and data source 16 17 We searched five electronic databases (PubMed, Web of science, Cochrane library, China National Knowledge Infrastructure database, medRxiv preprint server) to collect 18 19 relevant studies published until May 20, 2020. The search strategy was established and 20 performed by authors. The search terms used included following: two

(angiotensin-converting-enzyme inhibitor OR ACEI OR angiotensin-receptor blockers OR

1 ARB) AND (coronavirus OR COVID-19 OR SARS-CoV-2). There was no language

limitation on the search. All references of included studies were evaluated for additional

studies to include as many eligible studies as possible. For retrieved records, we used

reference management software (NoteExpress, college version) to save and filter.

2.2 Study selection

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

First, we reviewed the title and abstract of retrieved studies and excluded irrelevant ones. Then, we read through the full-text of remaining studies and included eligible studies based on our inclusion and exclusion criteria. Our inclusion criteria are as follows: (1) participants were patients diagnosed with COVID-19; (2) patients were reported as having ACEI and/or ARB exposure and non-ACEI and/or ARB exposure (ACEI use versus non-ACEI use; ARB use versus non-ARB use; ACEI/ARB use versus non-ACEIARB use); (3) at least one of following outcomes of COVID-19 was reported: positive rate/infection rate, hospital admission rate, severity, mortality in groups of ACEI and/or ARB exposure and non-ACEI and/or ARB exposure or the association between ACEI and/or ARB exposure and the risk of infection, hospital admission, severity, and death due to COVID-19; (4) the study design was case-control or cohort. Exclusion criteria are as follows: (1) the studies were reviews, case-reports, or animal experiments; (2) studies did not meet the inclusion criteria; (4) The data of interest was not reported; (4) no clear definition or diagnose methods of COVID-19. Two authors (Guangbo Qu and Liqin Shu) conducted the selections independently, and any disagreement was solved through discussion.

2.3 Data extraction and quality assessment

Following information was extracted using a standard chart form: first author's name, number of patients, number of patients in ACEI/ARB exposure (only ACEI exposure, only ARB exposure, either ACEI or ARB exposure) and non-exposure groups, patients' characteristics, infection risk, hospital admission, severity, and mortality of patients in each group, odds ratios (ORs) or risk ratios (RRs) or hazard ratio (HRs) of the infection, hospital admission, severity, and mortality of COVID-19.

Considering that the included studies were observational studies, the Newcastle-Ottawa Scale (NOS) was used to assess the quality from three aspects: (1) selection of participants; (2) comparability of groups; (3) assessment of exposure and outcome [15]. NOS contained eight items with scores ranging from 0 to 9 stars. The quality of studies was divided into three categories based on the scores: low quality is 0-3 stars, moderate quality is 4-5 stars, and high quality is 6 stars or above. Two authors (Guangbo Qu and Liqin Shu) assessed quality

3. Statistical analysis

Meta-analyses were conducted to assess for associations. Crude and adjusted odds ratios (Crude OR and Adjusted OR), with corresponding 95% confidence intervals, were calculated using the extracted binary data or effect sizes that was reported in all studies. Additionally, if available, Crude OR and/or Adjusted OR were also calculated to explore the association

independently, and disagreement was resolved by consensus.

between ACEI/ARB use and outcomes of COVID-19 among patients with hypertension. The 1 2 statistical heterogeneity between studies was identified using the Cochrane's Q test and I-square test. Heterogeneity was present if P value of Q test was less than 0.1 or the value of 3 I² was more than 50% [16]. The model for meta-analyses was chosen based on the level of 4 5 heterogeneity between studies; if obvious heterogeneity was present, then random-effects model was used, otherwise, the fix-effects model was used [17]. Subgroup analysis was 6 7 conducted based on the characteristics of included studies. Publication bias was identified via Begg's and Egger's tests. If P value of Begg's and Egger's tests were more than 0.05, then 8 9 publication bias is present. Sensitivity analysis was performed by omitting studies one by one to assess the stability of pooled results. All statistical analyses were performed using STATA 10

4. Results

11

12

13

14

15

16

17

18

19

20

21

4.1 Characteristics of included studies

software (version 14.0) and Review Manager (version 5.3).

After initial search, 477 records were retrieved (PubMed: n=166, Web of science: n=228, Cochrane library: n=9, China National Knowledge Infrastructure database: n=27, medRxiv preprint server: n=41, Other sources: n=6). 27 records were excluded for duplication. After reading the titles and abstracts, 391 records were excluded due to irrelevance. After study selection according to the inclusion and exclusion criteria, 36 articles were excluded and one study was further excluded because it was retracted by the journal. Finally, 22 articles containing 157,328 patients were included in this meta-analysis [8, 10, 18-37]. The flow chart

of the selection process is displayed in Figure 1.

The characteristics of included studies were shown in Table 1. Of included studies, 11 were conducted in China [8,16,20,21,22,24,25,27,33,35,36], six were from the United States [19,23,29,32,34,37], two were from Italy [10,30], one from Spain [26], one from United Kingdom [28], and one from Belgium [31]. All, but three, were cohort studies. The sample size of each study ranged from 42 to 37,031. Multiple comorbidities were reported and all patients in eight of the studies had hypertension [8,18,22,25,27,32,33,37]. Majority of the studies were high quality studies. Detailed quality assessment results are in Table S1.

4.2 ACEI/ARB use and COVID-19 infection

9

10

11 Pooled meta-analyses showed that, without adjusting for any confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection 12 (Crude OR: 1.27, 95% CI: 0.95-1.69 for ACEI use; Crude OR: 1.07, 95% CI: 0.76-1.50 for 13 ABR use; Crude OR: 1.10, 95% CI: 0.84-1.43 for ACEI/ARB use); however, obvious 14 heterogeneity was present between studies (All I² >50%) (Table 2, Figure 2). Similarly, after 15 16 adjusting for confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection (Adjusted OR: 0.94, 95% CI: 0.87-1.01, I²=0 for ACEI 17 use; Adjusted OR: 0.73, 95% CI: 0.49-1.09, I²=95.1% for ABR use; Adjusted OR: 0.96, 95% 18 CI: 0.91-1.01, I²=5.8% for ACEI/ARB use). Furthermore, subgroup analysis based on 19 20 different characteristics of studies showed no correlation between the use of ACEI and/or ARB and risk of COVID-19 infection. 21

4.3 ACEI/ARB use and hospital admission for COVID-19

Pooled meta-analyses showed that patients using ACEI, ARB, and ACEI/ARB had

higher risk of hospital admission for COVID-19 compared to patients not using these

medications (Adjusted OR: 1.29, 95% CI: 1.07-1.57, I²=62.4% for ACEI use; Adjusted OR:

6 1.69, 95% CI: 1.46-1.96, I²=0 for ABR use; Adjusted OR: 1.38, 95% CI: 1.21-1.57, I²=34.5%

7 for ACEI/ARB use) (Table 2 and Figure 3).

1

2

4

5

8

9

11

12

13

14

15

16

17

18

19

20

21

4.4 ACEI/ARB use and severity of COVID-19

Use of ACEI, ARB, and ACEI/ARB was not associated with severity of COVID-19

infection for both pooled crude and adjusted OR (Adjusted OR: 0.90, 95% CI: 0.72-1.14,

I²=0 for ACEI use; Adjusted OR: 0.91, 95% CI: 0.74-1.13, I²=45.8% for ABR use; Adjusted

OR: 0.90, 95% CI: 0.77-1.05, $I^2=27.6\%$ for ACEI/ARB use). Additionally, subgroup analysis

based on different characteristics (study design, region, race, study quality) also did not show

any significant association (Table 2 and Figure 4). Furthermore, for patients with

hypertension, ACEI, ARB, and ACEI/ARB use was not significantly associated with severity

of COVID-19 infection (Table S2).

4.5 ACEI/ARB use and COVID-19 related mortality

Only one study reported the association between ACEI and ARB use and risk of death

from COVID-19 without adjusting confounders separately (OR: 0.91, 95% CI: 0.38-2.17 for

ACEI use; OR: 0.77, 95% CI: 0.41-1.43 for ABR use) [18]. Only one study reported no 1 significant association between ACEI use and risk of death from COVID-19 (OR: 0.97, 95% 2 CI: 0.69-1.34) [30]. The pooled crude OR showed no significant association between 3 ACEI/ARB use and risk of death from COVID-19 (Crude OR: 0.88, 95% CI: 0.66-1.18, 4 5 I²=60.9%). However, the pooled adjusted ORs showed that patients on ACEI/ARB had a lower risk of death from COVID-19 (Adjusted OR: 0.66, 95% CI: 0.44-0.99, I^2 =57.9%). No 6 study reported the association between ARB use and the risk of death from COVID-19 (Table 7 2 and Figure 5). Furthermore, subgroup analysis on studies from China or studies of Asian 8 9 population found that ACEI/ARB use was associated with a lower risk of death from COVID-19. For patients with hypertension, ACEI/ARB use also was associated with a lower 10 11 risk of death from COVID-19 (Adjusted OR: 0.36, 95% CI: 0.17-0.77, I²=0) (Table S3). 12 4.6 Publication bias and results of sensitivity analysis 13 There was no significant publication bias among meta-analyses with two or more studies 14 included (All P values were more than 0.05) based on Begg's and Egger's tests (Table S4). 15 16 Sensitivity analysis showed that no study had significant impact on the stability of pooled 17 results from meta-analyses. 18 5. Discussion 19 The effect of ACEI/ARB use on COVID-19 patients has been a controversial topic since 20 the beginning of this pandemic. Based on prior studies on the effect of ACEI/ARBs on ACE2 21

expression [7, 38, 39], it was initially hypothesized that increased expression of ACE2 from 1 2 ACEI/ARB may increase the risk of SARS-COV-2 entrance into respiratory epithelial cells through binding to the structural transmembrane ACE2 receptor. Therefore, ACEI/ARB may 3 4 theoretically increase the susceptibility of infection and lead to worse outcomes from 5 COVID-19 [11, 40]. However, even though elevated expression of ACE2 caused by 6 ACEI/ARB use has been found in animal studies [7, 38, 39], no evidence has indicated 7 similar effects in human studies. Many studies have been published in the recent months 8 attempting to better understand the effects of ACEI/ARB in COVID-19 patients [8, 10, 19, 29, 9 30]. Our systematic review and meta-analysis shows that ACEI/ARBs use is not significantly 10 associated with increased infection risk and severity of COVID-19 and is actually associated 11 with a decreased risk of death from COVID-19. However, it does lead to an increased risk of 12 hospital admissions. The increased risk of hospitalization admissions in patients on 13 14 ACEI/ARB should be interpreted with caution because in the included studies, residual 15 confounding factors such as comorbidities like CVD were not well adjusted for [19, 30]. 16 Patients who are taking ACEI/ARB likely have underlying cardiovascular comorbidities and 17 prior studies demonstrated that patient comorbidities including hypertension and CVD are associated with severe COVID-19 infections, requiring hospitalization, and increased 18 mortality [41, 42]. Therefore, additional large, prospective, randomized studies are needed to 19 20 better characterize the effect of ACEI/ARB use on rate of hospitalization of COVID-19 patients. 21

Interestingly, the pooled crude ORs did not show significant association between 1 2 ACEI/ARB use and the risk of death from COVID-19, but after pooling the adjusted ORs, ACEI/ARB use was associated with a decreased risk of death from COVID-19 in all patients 3 and in those with hypertension. However, the crude OR did not found a significant 4 5 association of ACEI use and the risk of death from COVID-19. This difference seen bet the crude and adjusted ORs is likely because some important confounders were adjusted for 6 7 adjusted ORs, which may reflect the true association between ACEI/ARB use and risk of 8 death from COVID-19. Additionally, none of the studies reported the association between 9 ARB use and risk of death from COVID-19; therefore, pooled adjusted OR for ARBs was not calculated. 10 ACEI/ARBs are commonly used in the treatment of hypertension and CHF to inhibit 11 Angiotensin II and downregulate the Renin-angiotensin-aldosterone system (RAAS) [43]. 12 13 The decreased risk of death is likely due to continued management of patients' existing 14 underlying diseases as poorly controlled hypertension and CHF are both associated with worse outcomes in COVID-19 patients [44]. Additionally, the anti-inflammatory and 15 immune-modulatory properties of ACEI/ARBs may also explain their protective effect. 16 17 Heightened inflammatory response is an important factor leading to adverse outcomes of COVID-19 patients [45]. Previously, it has been shown that Angiotensin II increases 18 expression of inflammatory cytokines via activation of Angiotensin II receptor type 1 (AT1R) 19 20 [46]. ACEI/ARB decreases the level of Angiotensin II, potentially attenuating the inflammatory response. Additionally, ACEI/ARB reduces T-cell depletion in peripheral blood 21

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

13

and inhibits dendritic cell maturation and Th1 and Th17 cell polarization, resulting in a more potent immune system [47]. This hypothesis is supported in the study by Meng et al, in which it was demonstrated that ACEI/ARB use in COVID-19 patients was associated with lower IL-6 level, increased CD3 and CD8 T-cell counts, and decreased peak viral load [25]. This systemic review and meta-analysis comprehensively explored the effect of ACEI/ARB use on infection risk and different clinical outcomes related to COVID-19. Our study is consistent with results from prior studies on this topic, where they also demonstrated that ACEI/ARB use does not increase the severity of COVID-19 infection and decreases mortality [48-50]. Additionally, we also included information not available in previous systemic reviews such as the association between ACEI/ARB use and hospitalization due to COVID-19. This study helps to shed light into the current debate on the use of ACEI/ARBs in patients with COVID-19 and demonstrates that ACEI/ARB use does not lead to increased risk of COVID-19 infection and may even decrease the risk of death from COVID-19. The results from this study supports the joint statement from American Heart Association (AHA), Heart Failure Society of America (HFSA) and American College of Cardiology (ACC) and the statement from the European Society of Cardiology (ESC) Council on Hypertension that patients with COVID-19 taking ACEI/ARBs should continue their treatment [51]. A few limitations present in our study should be noted. First, all the studies included are observational studies, making it difficult to infer accurate causation. Second, no data was provided regarding the dose and exposure duration of ACEI/ARBs; therefore, we could not

determinate whether COVID-19 infection is affected by the dose and duration of ACEI/ARBs

exposure. Third, beta blockers can also prevent ACE2 activity [52], therefore, the effect of

14

ACEI/ARB use may be underestimated for patients with CVD who also take beta blockers.

Finally, given that some important confounders (such as comorbidities) have not been

adjusted for in the included studies, the true association between ACEI/ARB use and the risk

of hospitalization could not be well inferred.

Conclusion

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

In conclusion, ACEI/ARB use does not affect the risk and severity of COVID-19

infection and actually leads to a decreased mortality from COVID-19. The effect of

ACEI/ARB use on hospitalization needs to be further assessed with adjusting for potential

confounders. The potential protective role of ACEI/ARB supports the recommendation that

these agents should not be discontinued for COVID-19 patients if they are already on them.

6. Acknowledgements

Guangbo Qu and Chenyu Sun contributed to the study design, the development of

research protocol, and supervision of whole steps of this study. Liqin Shu designed the search

strategy and conducted the literature search. Guangbo Qu and Liqin Shu conducted study

selection, data extraction and quality assessment of included studies. Chenyu Sun checked the

literature search and data extraction. Guangbo Qu performed data analyses and created tables

and figures. Guangbo Qu and Chenyu Sun took responsibility for the interpretation of results.

Guangbo Qu wrote the first draft of manuscript. Liqin Shu, Evelyn J. Song, Ce Cheng,

- 1 Dhiran Verghese, John Patrick Uy, Qin Zhou, Hongru Yang, Zhichun Guo, Chenyu Sun
- 2 contributed to the edition and revision of the draft of manuscript. All authors reviewed and
- 3 approved final version of the manuscript.
- 4 .

5

9

12

13

6 7. Funding

- 7 This study is financially supported by Hunan Provincial Key Laboratory of Clinical
- 8 Epidemiology. (2020ZNDXLCL002)

10 8. Disclosure of interest

The authors have no interest to disclosure.

Reference

- 14 [1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
- Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus
- Investigating and Research Team. A novel coronavirus from patients with pneumonia in
- 17 China, 2019. N Engl J Med 2020; 382: 727-733.
- 18 [2] Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J
- 19 *Physiol Endocrinol Metab* 2020; 318: E736-E741.
- 20 [3] World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report –
- 135. Geneva, Switzerland: World Health Organization; June 3, 2020. Available online:

- 1 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid
- 2 -19-sitrep-135.pdf?sfvrsn=39972feb_2
- 3 [4] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T,
- 4 Zhang X, Zhang L. Epidemiological and Clinical Characteristics of 99 Cases of 2019
- Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. *Lancet* 2020; 395:
- 6 507-513.
- 7 [5] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and Impact of
- 8 Cardiovascular Metabolic Diseases on COVID-19 in China. *Clin Res Cardiol* 2020; 109:
- 9 531-538.
- 10 [6] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL,
- Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B,
- 12 Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH,
- Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY,
- 14 Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical
- 15 Treatment Expert Group for COVID-19. Comorbidity and Its Impact on 1590 Patients
- With COVID-19 in China: A Nationwide Analysis. *Eur Respir J* 2020; 55: 2000547.
- 17 [7] Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI,
- Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II
- receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:
- 20 2605-2610.
- 21 [8] Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai JL, Yang R, Han J, Huang Y, He S.

1 Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical

- 2 Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective
- 3 Study. *Hypertension* 2020; 76: 51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143.
- 4 [9] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL,
- 5 Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a
- functional receptor for the SARS coronavirus. *Nature* 2003; 426: 450-454.
- 7 [10] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone
- 8 System Blockers and the Risk of Covid-19. N Engl J Med 2020 May 1. doi:
- 9 10.1056/NEJMoa2006923. [Epub ahead of print].
- 10 [11] Diaz JH. Hypothesis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin
- 11 Receptor Blockers May Increase the Risk of Severe COVID-19. *J Travel Med* 2020 Mar
- 18. doi: 10.1093/jtm/taaa041. Online ahead of print.
- 13 [12] Fang L, Karakiulakis G, Roth M. Are Patients With Hypertension and Diabetes Mellitus
- at Increased Risk for COVID-19 Infection? *Lancet Respir Med* 2020; 8: e21.
- 15 [13] G O'Mara. Could ACE inhibitors, and particularly ARBs, Increase susceptibility to
- 16 COVID-19 infection? *BMJ* 2020; 368: m406.
- 17 [14] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items
- for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6:
- 19 e1000097.
- 20 [15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the
- quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603-605.

- 2 meta-analyses. *BMJ* 2003; 327: 557-560.
- 3 [17] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;
- 4 21: 1539-1558.
- 5 [18] Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System
- 6 Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for
- 7 Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020
- 8 Apr 23. doi: 10.1001/jamacardio.2020.1624. [Epub ahead of print].
- 9 [19] Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE,
- Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB,
- 11 Chung MK. Association of Use of Angiotensin-Converting Enzyme Inhibitors and
- Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019
- 13 (COVID-19). JAMA Cardiol 2020 May 5. doi: 10.1001/jamacardio.2020.1855. [Epub
- ahead of print].
- 15 [20] Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K,
- Zeng QT. [Clinical characteristics and outcomes of 112 cardiovascular disease patients
- infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48: E004. [Article in
- 18 Chinese]
- 19 [21] Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Oian J, Yu
- 20 K, Gong H, Ge J. The effect of RAS blockers on the clinical characteristics of
- 21 COVID-19 patients with hypertension. *Ann Transl Med* 2020; 8: 430.

- 1 [22] Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M,
- 2 Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q,
- Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M,
- 4 Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L,
- 5 Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors
- and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension
- 7 Hospitalized With COVID-19. *Circ Res* 2020; 126: 1671-1681.
- 8 [23] Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A,
- 9 Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y,
- Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk
- of Covid-19. N Engl J Med 2020 May 1. doi: 10.1056/NEJMoa2008975. [Epub ahead of
- print].
- 13 [24] Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu
- 14 X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19
- with Different Severity: A Multicenter Study of Clinical Features. *Am J Respir Crit Care*
- *Med* 2020; 201: 1380-1388.
- 17 [25] Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L,
- 28 Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of
- 19 COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020; 9: 757-760.
- 20 [26] de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A,
- Laredo L, Laosa O, Centeno-Soto GA, Gálvez MA, Puerro M, González-Rojano E,

20 1 Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodrí guez-Miguel A, Rodríguez-Puyol D, MED-ACE2-COVID19 study group. Use of 2 renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring 3 admission to hospital: a case-population study. Lancet 2020; 395: 1705-1714. 4 5 [27] Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, Han J, Song W, Huang Q, Chen Z. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center 6 7 retrospective observational medRxiv preprint 2020. doi: study. 10.1101/2020.04.06.20054825. 8 9 [28] Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, Roguski L, Noor K, Shek A, o'gallagher K, Zakeri R, Shah A, Teo J, Dobson RJB. ACE-inhibitors and 10 Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 11 infection in a multi-site UK acute Hospital Trust. medRxiv preprint 2020. doi: 12 13 10.1101/2020.04.07.20056788. [29] Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King Jr JT, Skanderson M, Hauser RG, 14 Schultze A, Jarvis CI, Holodniy M, Re III VL, Akgun KM, Crothers K, Taddei TH, 15 Freiberg MS, Justice AC. Covid-19 Testing, Hospital Admission, and Intensive Care 16 17 Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv preprint 2020. doi: 10.1101/2020.04.09.20059964. 18 [30] Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, The Reggio 19 Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of 20

SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv preprint 2020.

- 2 [31] De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, Dobson R,
- Wynendaele E, Van De Wiele C, Vandaele F, Van Dijck D, Bean D, Fedson D, De
- 4 Spiegeleer B. The effects of ARBs, ACEIs and statins on clinical outcomes of
- 5 COVID-19 infection among nursing home residents. Journal of the American Medical
- 6 Directors Association. 2020. doi: 10.1016/j.jamda.2020.06.018.
- 7 [32] Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer
- 8 SB, Vojta D, Krumholz HM. Association of Angiotensin-Converting Enzyme Inhibitors
- 9 and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in
- Hypertensive Patients with Coronavirus Disease-19. medRxiv preprint 2020. doi:
- 11 10.1101/2020.05.17.20104943.
- 12 [33] Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, Wang Z, Li X, Zhang S, Ye L, Lv J, Wei J,
- 13 Xie T, Gao H, Xu KF, Wang F, Liu L, Jiang C. Anti-hypertensive Angiotensin II receptor
- blockers associated to mitigation of disease severity in elderly COVID-19 patients.
- *medRxiv preprint* 2020. doi: 10.1101/2020.03.20.20039586.
- 16 [34] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the
- 17 Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD,
- Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J,
- 19 Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM,
- Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics,
- 21 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

- 1 New York City Area. *JAMA* 2020; 323: 2052-2059.
- 2 [35] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z.
- 3 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease
- 4 2019 (COVID-19). *JAMA Cardiol* 2020; e201017.
- 5 [36] Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, Wang H, Tan X, Du J, Jin S,
- 6 Huang K, Jiang F, Zhang S, Zheng N, Hu Y, Cai T, Aithal GP. Role of Drugs Affecting
- 7 the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19:
- 8 A Large Case-Control Study from Zheijang Province, China. *medRxiv preprint* 2020. doi:
- 9 10.1101/2020.04.24.20077875.
- 10 [37] Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, Goldberg SL.
- 11 Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with
- 12 Covid-19. *medRxiv preprint* 2020. doi: 10.1101/2020.04.24.20077388.
- 13 [38] Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression.
- 14 *Curr Hypertens Rep* 2008; 10: 410-414.
- 15 [39] Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination
- Renin-Angiotensin System Blockade and Angiotensin-Converting Enzyme 2 in
- 17 Experimental Myocardial Infarction: Implications for Future Therapeutic Directions.
- 18 *Clin Sci (Lond)* 2012; 123: 649-658.
- 19 [40] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients With COVID-19 Infection
- Taking ACEI/ARB. Curr Cardiol Rep, 202; 22: 31.
- 21 [41] Wang B, Li R, Lu Z, Huang Y. Does Comorbidity Increase the Risk of Patients With

- 2 [42] Mantovani A, Beatrice G, Dalbeni A. Coronavirus Disease 2019 and Prevalence of
- 3 Chronic Liver Disease: A Meta-Analysis. *Liver Int* 2020 Apr 4. doi: 10.1111/liv.14465.
- 4 [43] Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's
- 5 perspective. *Mini Rev Med Chem* 2006; 6: 491-497.
- 6 [44] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection
- 7 Taking ACEI/ARB. Curr Cardiol Rep 2020; 22: 31. doi:10.1007/s11886-020-01291-4.
- 8 [45] Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, Monte AD,
- 9 Bove T, Curcio F, Bassi F, Vita SD, Tascini C. Profiling COVID-19 Pneumonia
- 10 Progressing Into the Cytokine Storm Syndrome: Results From a Single Italian Centre
- 11 Study on Tocilizumab Versus Standard of Care. J Clin Virol 2020; 104444. doi:
- 12 10.1016/j.jcv.2020.104444.
- 13 [46] Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Liu S, Mehta JL. Cross-talk between
- inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes
- with AT1R and AT2R cDNA. Exp Biol Med 2012; 237: 1394-1401.
- 16 [47] Liu J, Zhang PS, Yu Q, Liu L, Yang Y, Guo FM, Qiu HB. Losartan inhibits conventional
- dendritic cell maturation and Th1 and Th17 polarization responses: Novel mechanisms
- of preventive effects on lipopolysaccharide-induced acute lung injury. *Int J Mol Med*
- 19 2012; 29: 269-276.
- 20 [48] Aref A. Abdulhak B, Kashour T, Noman A, Tlayjeh H, Mohsen A, Al-Mallah MH,
- Tleyjeh IM. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor

Blockers and Outcome of COVID-19: A Systematic Review and Meta-analysis. 1 2 medRxiv preprint 2020. doi: 10.1101/2020.05.06.20093260. [49] Zhang X, Yu J, Pan L, Jiang HY. ACEI/ARB Use and Risk of Infection or Severity or 3 Mortality of COVID-19: A Systematic Review and Meta-analysis. Pharmacol Res 2020 4 5 May 15: 104927. doi: 10.1016/j.phrs.2020.104927. [50] Ghosal S, Mukherjee Jagat J, Sinha B, Gangopadhyay KK. The effect of angiotensin 6 7 converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis. 8 9 medRxiv preprint 2020. doi: 10.1101/2020.04.23.20076661. [51] American Heart Association (AHA), Heart Failure Society of America (HFSA) and 10 11 American College of Cardiology (ACC). Patients taking ACE-i and ARBs who contract 12 COVID-19 should continue treatment, unless otherwise advised by their physician. 2020. 13 [52] Wang Y, Moreira Mda C, Heringer-Walther S, Schultheiss HP, Siems WE, Wessel N, 14 Walther T. Beta blockers prevent correlation of plasma ACE2 activity with 15 echocardiographic parameters in patients with idiopathic dilated cardiomyopathy. J 16 17 Cardiovasc Pharmacol 2015; 65: 8-12. 18 19 20

Figure legends

1

21

2 Figure 1. Flow diagram of study selection for this systematic review and meta-analysis. Figure 2. Pooled results of meta-analyses for the association between ACEI/ARB use and risk 3 4 of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus 5 non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus 6 7 non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus 8 non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus 9 non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus 10 non-ACEI/ARB use. 11 Figure 3. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of hospital admission for COVID-19. (A) Pooled adjusted OR for the comparison between 12 13 ACEI use versus non-ACEI use; (B) Pooled adjusted OR for the comparison between ARB 14 use versus non-ARB use; (C) Pooled adjusted OR for the comparison between ACEI/ARB 15 use versus non-ACEI/ARB use. Figure 4. Pooled results of meta-analyses for the association between ACEI/ARB use and risk 16 17 of severity of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus 18 19 non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus 20 non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus

non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus

non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use. Figure 5. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of death from COVID-19. (A) Pooled crude OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use; (B) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use. **Tables** Table 1. Characteristics of included studies. Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

Table 1. Characteristics of included studies.

First author	Year	Region	Race	Study design	Total	ACEI/ARB exposure	Non-ACEI/ARB exposure	Age (years)	Male/Female	Diagnostic criteria of COVID-19	Comorbidity	Comparison groups	Reported association outcome	Quality
LiJ[18]	2020	China	Asian	Retrospective cohort	362	115	247	66.0 (59.0-73.0)		The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (100%); Cerebrovascular disease (18.8%); Coronary heart disease(17.1%); Heart failure(2.8%); Diabetes (35.1%); Digestive disorder(21.5%); Respiratory disease(5.0%); Neurological disease(10.5%); Solid tumor(3.0%); Chronic renal disease(9.7%)	ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI vs Other drugs; ARB vs Other drugs ACEI vs ARB ACEI vs ARB	Severity and death risk	Moderate
Mehta N[19]	2020	United States	Mixed	Retrospective cohort	18,472	2,285	16,187	49±21	7384/12725	Laboratory testing using RT-PCR	Diabetes(n=86); Coronary artery disease(n=58); Hypertension (n=186); Chronic obstructive pulmonary disease (n=46); Heart failure (n=52)	ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI/ARB vs Non–ACEI/ARB	Infection and death risk	Moderate
Peng YD [20]	2020	China	Asian	Retrospective cohort	112	22	90	62.0 (55.0-67.0)		The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (82.1%);Coronary heart disease (55.4%); Heart failure (35.7%); Diabetse (20.5%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate
Huang Z	2020	China	Asian	Retrospective cohort	50	20	30	52.65±13.12 for ACEI/ARB exposure; 67.77±12.84 for Non-ACEI/ARB exposure	27/23	The diagnosis and treatment scheme for COVID-19 of Chinese (6th edition).	Diabetes(8.0%); Coronary heart disease(2.0%); Chronic obstructive pulmonary disease(2.0%); Anemia (2.0%)	ACEI/ARB vs Non-ACEI/ARB	Severity and death risk	Moderate

								64 (55-68) for		New Coronavirus Pneumonia				
								ACEI/ARB		Prevention and Control	Hypertension (100%); Diabetes (n=244); Coronary heart			
Zhang P	2020	China	Asian	Retrospective	1128	118	940	exposure;	603/525	Program (5th edition)	disease (n=131); Chronic renal diseases (n=35);	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
[22]	2020	Cimia	7 15/1111	cohort	1120	110	7.0	64 (57-69) fo		published by the National	Cerebrovascular diseases (n=41); Chronic liver disease	riedziako witon riedziako	Douil 11st	11.5.
								Non-ACEI/ARI	3	Health Commission of China	(n=21); Chronic obstructive pulmonary disease (n=6)			
								exposure		and WHO interim guidance				
								65 (57-72) for						
								ACEI/ARB		The Front Transition of the Control	W (1000) P. I (2000) P			
				Retrospective				exposure;			Hypertension (100%); Diabetes (30.2%); Respiratory disease			
Yang G [8]	2020	China	Asian	cohort	126	43	83	67 (62-75) for	62/64	Chinese National Health	(4.7%); Kidney disease (2.4%); Hepatic disease (6.3%);	ACEI/ARB vs Non–ACEI/ARB	Severity and death risk	High
								non-ACEI/ARI	3	Commission	Cardiopathy (18.3%); Neurological disease (7.9%)			
								exposure						
										Positive nasopharyngeal swab				
										specimens tested with at least				
						8071 for				two real-time				
Mancia G	2020	Italy	NA	Case-control	37031	ACEI;	NA	NA	23371/13660	reverse-transcriptase-	Cardiovascular disease (23.1%); Respiratory disease (6.4%);	ACEI vs Non–ACEI; ARB vs Non–ARB;	Infection risk	High
[10]					7	304 for ARB				polymerase-chain-reaction	Kidney disease (3.0%); Cancer (15.5%)	ARB VS NOII—ARB;		
										assays targeting different				
										genes of SARSCov-2.				

Reynolds HR [23]	2020	United States	Mixed	Retrospective cohort	AC 1328 12,594 AF 2319	4 for EEI; 8 for RB; 9 for or ARB	NA	49 (34–63)	5229/7365	A series of SARS-CoV-2 RNA test	Hypertension (34.6%); Heart failure (6.2%); myocardial infarction (4.2%); Diabetes (18.0%); Chronic kidney disease (9.6%); Obstructive lung disease (14.6%)	ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI/ARB vs Non-ACEI/ARB	Infection risk	High
Feng Y	2020	China	Asian	Retrospective cohort	8 for A 27 for 476 33 for or A	ARB;	NA	53(40-64)	271/205	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (23.7%); Cardiovascular disease (8.0%); Diabetes (10.3%); Malignancy (2.5%); Cerebrovascular disease (3.6%); Immunosuppression (1.5%); COPD (4.6%); Chronic nephropathy (0.8%); Others (21.6%)	ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI/ARB vs Non-ACEI/ARB	Severity risk	Moderate
Meng J [25]	2020	China	Asian	Retrospective cohort	42 1	7	25	64.5 (55.8–69.0)	24/18	The guidelines established by the National Health Commission of the People's Republic of China.	Hypertension (100%); other comorbidities (not reported)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate
de Abajo FJ [26]	2020	Spain	NA	Case-control	2433 12529 AC 1860 fc		NA	75.3±12.3	7645/4884	a PCR-confirmed diagnosis of COVID-19	Hypertension (50.0%); Diabetes (20.9%); Dyslipidaemia (31.7%); Ischaemic heart disease (7.8%); Heart failure (3.8%); Atrial fibrillation (8.8%); Thromboembolic disease (2.7%); Cerebrovascular accident (5.1%); COPD (8.3%); Asthma (5.7%); Cancer (14.2%); Chronic renal failure (5.3%)	ACEI vs Non-ACEI; ARB vs Non-ARB	Infection risk	High
Zeng Z	2020	China	Asian	Retrospective	75 2	8	47	67±11	35/40	the criteria of COVID-19 previously established by the WHO	Hypertension (100%)	ACEI/ARB vs Non–ACEI/ARB	Infection, severity and death risk	Moderate

Bean DM	2020	United Kingdom	Mixed	Retrospective cohort	1200	399	801	67.96 ±17.07	686/514	NA	Hypertension (53.8%); Diabetes(34.8%); HF(8.9%); IHD(13.3%); COPD(10.1%); Asthma(14.1%); CKD(17.2%); Stroke/TIA(19.6%)	ACEI/ARB vs Non-ACEI/ARB	Death risk	High
Rentsch CT[29]	2020	United States	Mixed	Retrospective cohort		1011 for ACEI; 563 for ARB; 1532 for ACEI or ARB	2778 for Non-ACEI; 3226 for Non-ARB; 2257 for Non-ACEI or ARB	65.7 (60.5-70.7)	3417/372	PCR tested positive for SARS-CoV-2	Asthma (7.5%); Cancer(15.1%); Chronic kidney disease (14.8%); COPD(26.2%); Diabetes (32.8%); Hypertension (65.0%); Liver disease (12.3%); Vascular disease (28.9%)	ACEI/ARB vs Non–ACEI/ARB	Infection, Hospitalization and ICU risk	High
Giorgi Rossi P[30]	2020	Italy	NA	Retrospective	2653	NA	NA	All age group	1328/1325	all symptomatic patients who tested positive with PCR	NA	ACEI vs Non-ACEI	Hospitalization and death	High
De Spiegeleer A [31]	2020	Belgium	NA	Retrospective	154	30	124	86±7	51/103	clinical grounds and/or PCR	Hypertension (25.3%); Diabetes(18.2%)	ACEI/ARB vs Non-ACEI/ARB	Infection and severity	High
Khera R	2020	United States	Mixed	Retrospective	10196	3083 for ACEI; 2957 for ARB	NA	≥18	4675/5521	PCR tested positive for SARS-CoV-2	Hypertension (100%)	ACEI vs Others; ARB vs Others; ACEI vs ARB	Hospitalization and death	High
Liu Y [33]	2020	China	Asian	Retrospective	46	2 for ACEI; 10 for ARB	NA	>65	NA	The diagnosis and treatment scheme for COVID-19 of Chinese	Hypertension (100%)	ACEI vs Non-ACEI; ARB vs Non-ARB	Severity risk	Moderate

Richardson S [34]	2020	United States	Mixed	Retrospective	5700 245 fo 413 fo	68 for ACEI; For ARB; For ACEI	953	63(52-75)	3437/2263	PCR tested positive for SARS-CoV-2	Hypertension (56.6%); Coronary artery disease(11.1%); COPD(5.4%); Cancer (6%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
Guo T [35]	2020	China	Asian	Retrospective	187	or ACEI	168 for Non-ACEI or ARB	58.50±14.66	91/96	The interim guidance of the World Health Organization	Hypertension (32.6%); CHD (11.2%); Cardiomyopathy(4.3%); Diabetes(15.0%); COPD (2.1%); Malignant neoplasm (7.0%); Chronic kidney disease (3.2%)	ACEI/ARB vs Non-ACEI/ARB	Death risk	High
Yan H [36]	2020	China	Asian	Case-control	53 fo 49,277 58 fo	r ACEI; or ARB; or ACEI	NA	48.75±14.19	23817/25460	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Diabetes(6.14%); Hypertension (20.28%); Cardio or cerebrovascular disease (1.3%); Tumour (2.0%)	ACEI vs Non-ACEI; ARB vs Non-ARB	Infection and severity risk	High
Andrew Ip	2020	United States	NA	Retrospective	1129	or ACEI	669 for Non-ACEI or ARB	NA	NA	NA	Hypertension (100%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate

Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

Subgroup	Number of studies	Crude OR	95%	%CI	P	I2(%)	Model	Number of studies	Adjusted OR	959	%CI	P	I2(%)	Model
Subgroup Analy	sis for Risk	of Infect	ion											
ACEI use vs nor	n-ACEI use													
Overall	4	1.27	0.95	1.69	0.103	91.9	R	4	0.94	0.87	1.01	0.106	0	F
Study design														
Case-control	2	1.16	1.08	1.24	< 0.001	12.2	F	2	0.96	0.86	1.06	0.381	0	F
Cohort	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Region														
China	1	0.72	0.3	1.72	0.461	NA	NA	1	0.65	0.27	1.6	0.348	NA	NA
Italy	1	1.16	1.08	1.24	< 0.001	NA	NA	1	0.96	0.87	1.07	0.439	NA	NA
United States	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Race														
Asian	1	0.72	0.3	1.72	0.461	NA	NA	1	0.65	0.27	1.6	0.348	NA	NA
Mixed	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Unknown	1	1.16	1.08	1.24	< 0.001	NA	NA	1	0.96	0.87	1.07	0.439	NA	NA
Quality														
High	4	1.27	0.95	1.69	0.103	91.9	R	3	0.94	0.87	1.03	0.192	0	F
Moderate	0	NA	NA	NA	NA	NA	NA	1	0.89	0.72	1.10	0.281	NA	NA
ARB use vs non-	-ARB use													
Overall	4	1.07	0.76	1.50	0.709	95.7	R	4	0.73	0.49	1.09	0.120	95.1	R

$\boldsymbol{\neg}$	$\boldsymbol{\gamma}$
4	•

Study design														
Case-control	2	0.80	0.35	1.81	0.59	97.0	R	2	0.48	0.13	1.86	0.289	98.2	R
Cohort	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Region														
China	1	0.52	0.40	0.68	< 0.001	NA	NA	1	0.24	0.17	0.34	< 0.001	NA	NA
Italy	1	1.20	1.12	1.29	< 0.001	NA	NA	1	0.95	0.86	1.05	0.314	NA	NA
United States	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Race														
Asian	1	0.52	0.40	0.68	< 0.001	NA	NA	1	0.24	0.17	0.34	< 0.001	NA	NA
Mixed	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Unknown	1	1.20	1.12	1.29	< 0.001	NA	NA	1	0.95	0.86	1.05	0.314	NA	NA
Quality														
High	4	1.07	0.76	1.50	0.709	95.7	R	3	0.64	0.38	1.06	0.083	96.6	R
Moderate	0	NA	NA	NA	NA	NA	NA	1	1.09	0.87	1.37	0.457	NA	NA
ACEI/ARB use vs	s non-ACI	EI/ARB u	se											
Overall	7	1.10	0.84	1.43	0.488	88.6	R	6	0.96	0.91	1.01	0.142	5.8	F
Study design														
Case-control	2	0.81	0.38	1.74	0.583	97.0	R	2	0.66	0.26	1.68	0.387	75.3	R
Cohort	5	1.31	0.96	1.77	0.089	71.8	R	3	0.97	0.89	1.05	0.425	0	F
Region														
China	3	0.75	0.47	1.21	0.241	70.2	R	1	0.36	0.14	0.93	0.035	NA	NA
United States	2	1.46	0.93	2.29	0.096	90.3	R	2	0.97	0.89	1.05	0.398	0	F
Belgium	1	1.52	0.64	3.61	0.343	NA	NA	1	2.72	0.42	17.74	0.296	NA	NA

34

Italy	1	1.18	1.12	1.24	< 0.001	NA	NA	1	0.96	0.89	1.03	0.273	NA	NA
Race														
Asian	3	0.75	0.47	1.21	0.241	70.2	R	1	0.36	0.14	0.93	0.035	NA	NA
Mixed	2	1.46	0.93	2.29	0.096	90.3	R	4	0.97	0.89	1.05	0.425	0	F
Unknown	2	1.18	1.12	1.24	< 0.001	0	F	1	0.96	0.89	1.03	0.273	NA	NA
Quality														
High	6	1.1	0.83	1.44	0.515	90.5	R	5	0.96	0.91	1.02	0.152	24.4	F
Moderate	1	1.15	0.39	3.37	0.799	NA	NA	1	0.97	0.81	1.16	0.733	NA	NA
Subgroup Analys	is for Risk	of Hospi	ital Adn	nission										
ACEI use vs non-	ACEI use													
Overall	NA	NA	NA	NA	NA	NA	NA	3	1.29	1.07	1.57	0.009	62.4	R
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.13	0.97	1.31	0.111	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	2	1.46	1.06	2.02	0.021	57.9	R
Region														
Italy	NA	NA	NA	NA	NA	NA	NA	1	1.30	1.11	1.52	0.001	NA	NA
United States	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.13	0.97	1.31	0.111	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
Unknown	NA	NA	NA	NA	NA	NA	NA	2	1.21	1.09	1.35	0.001	38.2	F
Quality														
High	NA	NA	NA	NA	NA	NA	NA	2	1.21	1.09	1.35	0.001	38.2	F

Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
ARB use vs non-A	ARB use													
Overall	NA	NA	NA	NA	NA	NA	NA	2	1.69	1.46	1.96	< 0.001	0	F
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	< 0.001	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Region														
United States	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	< 0.001	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Unknown	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	< 0.001	NA	NA
Quality														
High	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	< 0.001	NA	NA
Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.5	0.033	NA	NA
ACEI/ARB use v	s non-ACE	EI/ARB u	se											
Overall	NA	NA	NA	NA	NA	NA	NA	4	1.38	1.21	1.57	< 0.001	34.5	F
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.39	0.93	2.07	0.107	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	3	1.45	1.11	1.88	0.006	56.3	R
Region														
United States	NA	NA	NA	NA	NA	NA	NA	2	1.59	1.03	2.44	0.035	57.7	R
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.39	0.93	2.07	0.107	NA	NA

n

Italy	NA	NA	NA	NA	NA	NA	NA	1	1.30	1.11	1.52	0.001	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	2	1.59	1.03	2.44	0.035	57.7	R
Unknown	NA	NA	NA	NA	NA	NA	NA	2	1.31	1.14	1.52	< 0.001	0	F
Quality														
High	NA	NA	NA	NA	NA	NA	NA	3	1.31	1.14	1.50	< 0.001	0	F
Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.93	1.38	2.71	< 0.001	NA	NA
Subgroup Analys	sis for Risk	of Sever	ity											
ACEI use vs non-	ACEI use													
Overall	5	1.01	0.63	1.60	0.982	75.3	R	2	0.90	0.72	1.14	0.939	0	F
Study design														
Case-control	1	0.91	0.69	1.21	0.510	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Cohort	4	0.99	0.51	1.90	0.964	60.7	R	1	1.23	0.19	7.95	0.828	NA	NA
Region														
China	3	0.73	0.40	1.33	0.308	0	F	1	1.23	0.19	7.95	0.828	NA	NA
Italy	1	0.91	0.69	1.21	0.510	NA	NA	0	NA	NA	NA	NA	NA	NA
United States	1	1.63	1.34	1.99	0.001	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Race														
Asian	3	0.73	0.4	1.33	0.308	0	F	1	1.23	0.19	7.95	0.828	NA	NA
Mixed	1	1.63	1.34	1.99	0.001	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Unknown	1	0.91	0.69	1.21	0.510	NA	NA	0	NA	NA	NA	NA	NA	NA
Quality														

$\boldsymbol{\neg}$	$\boldsymbol{\neg}$
4	- /

High	2	1.34	1.14	1.58	< 0.001	91.0	R	2	0.90	0.72	1.14	0.939	0	F
Moderate	3	0.73	0.4	1.33	0.308	0	F	0	NA	NA	NA	NA	NA	NA
ARB use vs non-	ARB use													
Overall	5	0.75	0.41	1.39	0.090	91.8	R	3	0.91	0.74	1.13	0.409	45.8	F
Study design														
Case-control	1	0.83	0.63	1.10	0.190	NA	NA	1	0.77	0.36	1.64	0.498	NA	NA
Cohort	4	0.70	0.29	1.69	0.427	91.8	R	2	0.59	0.17	2.09	0.413	71.2	R
Region														
China	3	0.48	0.16	1.50	0.206	86.9	R	2	0.60	0.31	1.16	0.723	NA	NA
Italy	1	0.83	0.63	1.10	0.190	NA	NA	1	0.96	0.77	1.20	0.128	48.1	F
United States	1	1.76	1.47	2.10	< 0.001	NA	NA	0	NA	NA	NA	NA	NA	NA
Race														
Asian	3	0.48	0.16	1.50	0.206	86.9	R	2	0.60	0.31	1.16	0.723	NA	NA
Mixed	1	1.76	1.47	2.10	< 0.001	NA	NA	1	0.96	0.77	1.20	0.128	48.1	F
Unknown	1	0.83	0.63	1.10	0.190	NA	NA	0	NA	NA	NA	NA	NA	NA
Quality														
High	2	1.22	0.58	2.54	0.599	95.0	R	2	0.94	0.76	1.17	0.594	0	F
Moderate	3	0.48	0.16	1.50	0.206	86.9	R	1	0.25	0.06	1.01	0.052	NA	NA
ACEI/ARB use v	s non-ACE	I/ARB u	se											
Overall	11	0.75	0.48	1.17	0.201	88.7	R	4	0.9	0.77	1.05	0.197	27.6	F
Study design														
Case-control	1	0.87	0.71	1.06	0.173	NA	NA	1	0.82	0.41	1.65	0.578	NA	NA
Cohort	10	0.72	0.41	1.27	0.255	87.0	R	3	0.62	0.27	1.38	0.239	50.8	R

.,	v
J	

Region														
China	8	0.61	0.34	1.09	0.093	73.8	R	2	0.53	0.17	1.63	0.269	55.0	R
United States	1	1.87	1.62	2.16	< 0.001	NA	NA	1	0.93	0.79	1.09	0.377	NA	NA
Belgium	1	0.79	0.29	2.16	0.647	NA	NA	1	0.48	0.11	2.13	0.334	NA	NA
Italy	1	0.87	0.71	1.06	0.173	NA	NA	0	NA	NA	NA	NA	NA	NA
Race														
Asian	8	0.61	0.34	1.09	0.093	73.8	R	2	0.53	0.17	1.63	0.269	55.0	R
Mixed	1	1.87	1.62	2.16	< 0.001	NA	NA	1	0.93	0.79	1.09	0.377	NA	NA
Unknown	2	0.87	0.71	1.06	0.154	0	F	1	0.48	0.11	2.13	0.334	NA	NA
Quality														
High	4	1.05	0.59	1.88	0.860	92.6	R	3	0.92	0.79	1.07	0.279	0	F
Moderate	7	0.59	0.30	1.17	0.129	77.5	R	1	0.25	0.06	1.01	0.052	NA	NA
Subgroup Analysi	is for Risl	k of Death	1											
ACEI use vs non-	ACEI use	!												
Overall	2	0.51	0.19	1.38	0.185	74.6	R	2	0.52	0.15	1.82	0.307	93.8	R
Study design														
Case-control	0	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA
Cohort	2	0.51	0.19	1.38	0.185	74.6	R	2	0.52	0.15	1.82	0.307	93.8	R
Region														
China	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
Italy	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Multiple areas	1	0.33	0.20	0.54	< 0.001	NA	NA	1	0.27	0.16	0.46	< 0.001	NA	NA
Race														


$^{-}$	$^{\circ}$
4	ч

Asian	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
Mixed	1	0.33	0.20	0.54	< 0.001	NA	NA	1	0.27	0.16	0.46	< 0.001	NA	NA
Unknown	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Quality														
High	1	0.33	0.20	0.54	< 0.001	NA	NA	2	0.52	0.15	1.82	0.307	93.8	R
Moderate	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
ARB use vs non-A	ARB use													
Overall	2	1.1	0.81	1.49	0.531	39.5	F	NA	NA	NA	NA	NA	NA	NA
Study design														
Case-control	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cohort	2	1.1	0.81	1.49	0.531	39.5	F	NA	NA	NA	NA	NA	NA	NA
Region														
China	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
Multiple areas	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Race														
Asian	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
Mixed	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Quality														
High	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Moderate	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
ACEI/ARB use vs	s non-ACI	EI/ARB u	se											
Overall	11	0.87	0.66	1.15	0.322	57.0	R	5	0.51	0.31	0.84	0.009	78.4	R
Study design														

Case-control	0	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA
Cohort	11	0.87	0.66	1.15	0.322	57.0	R	5	0.51	0.31	0.84	0.009	78.4	R
Region														
China	6	0.74	0.42	1.30	0.299	32.5	F	2	0.36	0.17	0.77	0.009	0	F
United States	3	1.05	0.61	1.82	0.866	85.6	R	0	NA	NA	NA	NA	NA	NA
United Kingdom	1	0.83	0.64	1.07	0.155	NA	NA	1	0.63	0.47	0.84	0.002	NA	NA
Multiple areas	1	0.65	0.18	2.34	0.510	NA	NA	1	0.27	0.16	0.46	< 0.001	NA	NA
Italy	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Race														
Asian	6	0.74	0.42	1.30	0.299	32.5	F	2	0.36	0.17	0.77	0.009	0	F
Mixed	4	1.06	0.76	1.50	0.719	56.9	R	2	0.43	0.19	0.97	0.043	86.8	R
Unknown	1	0.66	0.51	0.86	0.002	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Quality														
High	5	0.88	0.59	1.34	0.571	75.9	R	5	0.51	0.31	0.84	0.009	78.4	R
Moderate	6	0.73	0.59	0.92	0.006	23.9	F	0	NA	NA	NA	NA	NA	NA

Records identified from five

electronic database (n=471)



22 articles were included for systematic review and meta-analysis

Records identified through

other sources (n=6)



				Odds Ratio		Odd	ls Ratio	s Ratio		
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95%	CI	IV, Rand	<u>dom, 95</u>	5% CI		
Mancia G 2020	0.148	0.035	32.3%	1.16 [1.08, 1.2	4]					
Rentsch CT 2020	0.582	0.065	30.9%	1.79 [1.58, 2.0	3]		•			
Reynolds HR 2020	0.131	0.1	28.6%	1.14 [0.94, 1.3	9]		•			
Yan H 2020	-0.329	0.445	8.2%	0.72 [0.30, 1.7	2]	_	•			
Total (95% CI)			100.0%	1.27 [0.95, 1.69	9]		•	ı		
Heterogeneity: Tau ² = 0 Test for overall effect: Z		df = 3 (I	P < 0.0000	01); I² = 92%	0.0 Favou	1 0.1 rs experimenta	1 I Favo	10 ours cont	100	


В

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% C	l		lds Ratio		
Mancia G 2020	0.182	0.036	26.8%	1.20 [1.12, 1.29]					
Rentsch CT 2020	0.531	0.058	26.3%	1.70 [1.52, 1.91]					
Reynolds HR 2020	0.113	0.122	23.9%	1.12 [0.88, 1.42]			*		
Yan H 2020	-0.654	0.139	23.1%	0.52 [0.40, 0.68]		7	•		
Total (95% CI)			100.0%	1.07 [0.76, 1.50]		1	*	ı	ı
Heterogeneity: Tau ² = 0 Test for overall effect: 2		df = 3 (I	P < 0.0000	•	0.01 avours e	0.1 experiment	1 al Favo	10 ours cont	100 rol

C

			Odds Ratio	Odds Ratio	
Study or Subgroup	log[Odds Ratio]	SE Weight	IV, Random, 95% CI	IV, Random, 95% CI	
De Spiegeleer A 2020	0.419 0.44	42 6.4%	1.52 [0.64, 3.62]	+-	
Mancia G 2020	0.166 0.03	26 20.5%	1.18 [1.12, 1.24]	•	
Rentsch CT 2020	0.157 0.08	89 18.9%	1.17 [0.98, 1.39]	•	
Reynolds HR 2020	0.615 0.1	12 18.0%	1.85 [1.49, 2.30]	-	
Yan H 2020	-0.616 0.13	33 17.1%	0.54 [0.42, 0.70]	*	
Yang G 2020	-0.062 0.19	92 14.5%	0.94 [0.65, 1.37]	+	
Zeng Z 2020	0.14 0.5	48 4.6%	1.15 [0.39, 3.37]		
Total (95% CI)		100.0%	1.10 [0.84, 1.43]	*	
Heterogeneity: Tau ² = 0.0	09; $Chi^2 = 52.27$, $df = 6$	$(P < 0.0000)^2$	1); l² = 89%)1 01 1 10 1	
Test for overall effect: Z =	= 0.69 (P = 0.49)		0.0 Favor	01 0.1 1 10 1 urs experimental Favours control	100







E

				Odds Ratio	Odds Ratio				
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% C	Î	IV, Rar	ndom, 9	5% CI	
Mancia G 2020	-0.051	0.051	26.6%	0.95 [0.86, 1.05]			•		
Mehta N 2020	0.086	0.116	24.8%	1.09 [0.87, 1.37]			•		
Reynolds HR 2020	0	0.074	26.1%	1.00 [0.86, 1.16]			•		
Yan H 2020	-1.427	0.177	22.4%	0.24 [0.17, 0.34]		-			
Total (95% CI)			100.0%	0.73 [0.49, 1.08]			•		
Heterogeneity: Tau ² = Test for overall effect:		df = 3 (I	P < 0.0000		0.01	0.1 experiment	1	10	100
				Г	avours t	xpeninent	ai ravo	Jui S Cont	101

F

Study or Subgroup	[]pol	SE	Weight	IV, Fixed, 95% (CI IV, F	ixed, 95%	6 CI	
De Spiegeleer A 2020	1.001	0.957	0.1%	2.72 [0.42, 17.76]]	-		
Mancia G 2020	-0.041	0.037	56.5%	0.96 [0.89, 1.03]]	•		
Mehta N 2020	-0.03	0.089	9.8%	0.97 [0.82, 1.16]]	†		
Rentsch CT 2020	-0.02	0.116	5.8%	0.98 [0.78, 1.23]]	+		
Reynolds HR 2020	-0.041	0.053	27.5%	0.96 [0.87, 1.06]]	•		
Yan H 2020	-1.022	0.486	0.3%	0.36 [0.14, 0.93]]			
Total (95% CI)			100.0%	0.96 [0.91, 1.01]		•		
Heterogeneity: $Chi^2 = 5.31$, $df = 5$ (P = 0.38); $I^2 = 6\%$					0.01 0.1	1	10	100
Test for overall effect: Z = 1.48 (P = 0.14)					Favours experimen	ıtal Favo	urs contro	ol






В

			Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio] SI	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Feng Y 2020	-1.427 0.372	17.9%	0.24 [0.12, 0.50]	
Li J 2020	0.199 0.249	20.8%	1.22 [0.75, 1.99]	-
Liu Y 2020	-1.079 0.499	14.9%	0.34 [0.13, 0.90]	
Mancia G 2020	-0.186 0.142	22.9%	0.83 [0.63, 1.10]	*
Reynolds HR 2020	0.565 0.09	23.5%	1.76 [1.47, 2.10]	•
Total (95% CI)		100.0%	0.75 [0.41, 1.39]	•
Heterogeneity: Tau² = 0 Test for overall effect: 2	0.41; Chi² = 48.85, df = 4 7 = 0.91 (P = 0.36)	(P < 0.000	. 0	.01 0.1 1 10 100
root for overall effect.	2 0.01 (1 0.00)		Favo	ours experimental Favours control

\mathbf{C}

Study or Subgroup	log[]	SE	Weight	IV, Random, 95% C	IV, Random, 95% CI
De Spiegeleer A 2020	-0.236	0.514	8.2%	0.79 [0.29, 2.16]	
Feng Y 2020	-1.561	0.568	7.4%	0.21 [0.07, 0.64]	
Huang Z 2020	-0.777	0.651	6.4%	0.46 [0.13, 1.65]	-
Li J 2020	0.104	0.227	13.2%	1.11 [0.71, 1.73]	-
Liu Y 2020	-0.916	0.411	9.9%	0.40 [0.18, 0.90]	
Mancia G 2020	-0.139	0.102	15.0%	0.87 [0.71, 1.06]	*
Peng YD 2020	-0.062	0.692	5.9%	0.94 [0.24, 3.65]	
Reynolds HR 2020	0.626	0.075	15.3%	1.87 [1.61, 2.17]	•
Yang G 2020	-0.315	0.392	10.2%	0.73 [0.34, 1.57]	
Zeng Z 2020	0.9	0.491	8.5%	2.46 [0.94, 6.44]	
Total (95% CI)			100.0%	0.86 [0.57, 1.31]	*
Heterogeneity: Tau ² = 0.29; Chi ² = 65.51, df = 9 (P < 0.00001); l ² = 86%					0.04 0.4 4 40 400
Test for overall effect: Z = 0.68 (P = 0.50)					0.01 0.1 1 10 100 Favours experimental Favours control






E


				Odds Ratio		Odds	Ratio	
Study or Subgroup	log[Odds Ratio]	SE W	<u>eight</u>	IV, Fixed, 95% C		IV, Fixed	l, 95% CI	
Liu Y 2020	-1.386 0.7	713	2.3%	0.25 [0.06, 1.01]			•	
Reynolds HR 2020	-0.041 0.1	115 8	9.7%	0.96 [0.77, 1.20]				
Yan H 2020	-0.261 0.3	385	8.0%	0.77 [0.36, 1.64]		-	_	
Total (95% CI)		10	0.0%	0.91 [0.74, 1.13]				
Heterogeneity: Chi ² = 3 Test for overall effect: 2	Fa	0.01	0.1 1 operimental	10 Favours co	100			


F


Study or Subgroup	log[]	SE	Weight	IV, Fixed, 95% (CI IV, Fixed	d, 95% CI	
De Spiegeleer A 2020	-0.734	0.76	1.1%	0.48 [0.11, 2.13]		
Liu Y 2020	-1.386	0.713	1.2%	0.25 [0.06, 1.01		•	
Reynolds HR 2020	-0.073	0.082	92.8%	0.93 [0.79, 1.09]		
Yan H 2020	-0.198	0.357	4.9%	0.82 [0.41, 1.65]		
Total (95% CI)			100.0%	0.90 [0.77, 1.05]	1		
Heterogeneity: Chi ² = 4.	13, df = 3	0.01 0.1	 1 10 100	١ ١			
Test for overall effect: Z	= 1.30 (F	Favours experimental		j			











L			Odds Ratio	Odds Ratio	
Study or Subgroup	log[Odds Ratio] SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Bean DM 2020	-0.462 0.148	27.3%	0.63 [0.47, 0.84]	-	
Giorgi Rossi P 2020	-0.03 0.169	26.6%	0.97 [0.70, 1.35]	*	
Mehra MR 2020	-1.309 0.269	22.6%	0.27 [0.16, 0.46]	-	
Yang G 2020	-1.139 0.784	7.9%	0.32 [0.07, 1.49]		
Zhang P 2020	-0.994 0.454	15.5%	0.37 [0.15, 0.90]	_	
Total (95% CI)		100.0%	0.51 [0.31, 0.84]	•	
Heterogeneity: Tau ² = 0	0.22; Chi ² = 18.57, df = 4	0); I ² = 78%	0.01 0.1 1 10 10	— 00	
Test for overall effect: 2	Z = 2.62 (P = 0.009)		-	ours experimental Favours control	00